newsfilter
← Latest News
ACCESS Newswire·

Protagonist Therapeutics to Participate in Four Investment Bank Conferences in November 2026

PTGX
  • Protagonist Therapeutics announced senior management will attend four investment bank conferences in November 2026.
  • The 8th Annual Wolfe Research Healthcare Conference is scheduled for November 10, 2026, in New York, NY, featuring a fireside chat from 1:20-1:50 p.m. EST & 1x1 meetings.
  • The Truist Securities 2026 Biopharma Symposium is set for November 12, 2026, in New York, NY, consisting of 1x1 meetings.
  • The UBS Global Biopharma Conference will take place on November 16, 2026, in London, UK, with a fireside chat from 12:40-1:10 p.m. GMT & 1x1 meetings.
  • The Jefferies Global Healthcare Conference is planned for November 17, 2026, in London, UK, featuring a fireside chat from 8:30-8:55 a.m. GMT & 1x1 meetings.
  • Replays of the presentations will be available on the Company's Investor Relations webpage for one year post-event.
  • Protagonist Therapeutics utilizes a proprietary peptide technology platform that has yielded two FDA-approved medicines: ICOTYDE™ & MIMRYLO™.
  • ICOTYDE™ (icotrokinra) is a targeted oral peptide licensed to Johnson & Johnson for moderate-to-severe plaque psoriasis, launched in the U.S. in March 2026, with Phase 3 development ongoing for psoriatic arthritis, ulcerative colitis, & Crohn's disease.
  • MIMRYLO™ (rusfertide) is a hepcidin mimetic peptide licensed to Takeda Pharmaceutical Company Limited for the treatment of erythrocytosis in adults with polycythemia vera (PV).
  • The Company maintains additional programs including an oral IL-17 antagonist peptide, anti-obesity dual & triple agonists, an oral hepcidin functional mimetic, & newly announced IL-4 & amylin discovery programs.